This prompted the development of PF-06873600, the first-in-class selective inhibitor of CDK2/4/6, which has demonstrated antitumor activity as a single agent and in combination with endocrine therapy (ET) in multiple in vivo tumor models (7, 8). Here, CDK2 is linked to neoplasm.